Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.57 |
| ▸ | NPY4R | P50391 | 4/20 | 0.52 |
| ▸ | NPY1R | P25929 | 2/20 | 0.52 |
| ▸ | NPY2R | P49146 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21981319 | 0.94 | REN (0.53) | RENKISS1RNPY4RNPY1ROPRK1 | |
| SCHEMBL21981320 | 0.94 | REN (0.53) | RENKISS1RNPY4RNPY1ROPRK1 | |
| SCHEMBL17553458 | 0.94 | PAX8 (0.52) | RENKISS1R | |
| SCHEMBL28269289 | 0.92 | NPY4R (0.53) | RENKISS1RNPY4RNPY1ROPRK1 | |
| SCHEMBL20173869 | 0.92 | REN (0.63) | RENKISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL23352495 | 0.92 | REN (0.56) | RENKISS1RNPY4RNPY1RNPY2R | |
| SCHEMBL20669110 | 0.92 | NPY4R (0.53) | RENKISS1RNPY4RNPY1ROPRK1 | |
| SCHEMBL22871636 | 0.90 | REN (0.52) | RENKISS1ROPRK1 | |
| SCHEMBL20173867 | 0.88 | REN (0.62) | REN | |
| SCHEMBL17254230 | 0.87 | PAX8 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018094335-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | CACNG6, KCNN3, SCN1B | REN 2892/4885KISS1R 2969/4885NPY4R 521/4885 |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | CACNG6, KCNN3, SCN1B | REN 2892/4885KISS1R 2969/4885NPY4R 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.